3 recruiting, 1 active not recruiting, 1 completed, 1 unknown. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 3, Active not recruiting 1, Completed 1, Unknown 1 |
Follow zimberelimab: new trials by email Literature Review of zimberelimab trials Research Report on zimberelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer | Phase 3 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 784 | 2026-06-24 | 2026-07-17 |
| Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. Zimberelimab, Sacituzumab govitecan, Cisplatin - Lung Diseases, Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | Fundación GECP | 129 | 2025-02-04 | 2026-05-18 |
| A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer GLS-010, Placebo, paclitaxel - Persistent, Recurrent, or Metastatic Cervical Cancer | Phase 3 | Recruiting | Guangzhou Gloria Biosciences Co., Ltd. | 424 | 2023-04-20 | 2026-09-16 |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body Domvanalimab, Zimberelimab, Capecitabine - Advanced Upper Gastrointestinal Tract Adenocarcinoma | Phase 3 | Completed | Arcus Biosciences, Inc. | 1040 | 2022-11-21 | 2026-09-03 |
| Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Zimberelimab, Domvanalimab, Pembrolizumab - Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Gilead Sciences | 1021 | 2022-10-12 | 2026-01-30 |
| GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) GLS-010, Chemotherapy of Investigator's choice - Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma | Phase 3 | Unknown | Guangzhou Gloria Biosciences Co., Ltd. | 60 | 2022-09-01 | 2022-08-26 |
Carcinoma, Non-Small-Cell Lung (2) · Recurrence (2) · Acrocephalosyndactylia (1) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Lung Diseases (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Stomach Neoplasms (1)
Guangzhou Gloria Biosciences Co., Ltd. (2) · Arcus Biosciences, Inc. (1) · Fundación GECP (1) · Gilead Sciences (1) · Taiho Pharmaceutical Co., Ltd. (1)
China (3) · Japan (3) · South Korea (3) · Spain (3) · Argentina (2) · Australia (2) · Brazil (2) · Canada (2) · Chile (2) · France (2) · Hong Kong (2) · Israel (2) · Italy (2) · Mexico (2) · Portugal (2)
2023 (1)